ROBIN HOWARD W (President & CEO) sold 11.9% of their position (6.67K shares) of NEKTAR THERAPEUTICS on the open market
Open‑market sale worth $311.2K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 4 sales
Filed: 9/11/2025ACC: 0000950170-25-114365
DirectorOfficer· President & CEO
Since Aug 2018
-6.67K
Net shares
Net seller
$311.2K
Total sold
4
Open market trades
0B · 4S
4
Total transactions
6.67K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
−2.10K
Price / share
$45.16
Trade value
$94.84K
% of position
3.7%
9/9/2025
56.01K→53.91K
Common Stock
Direct
Shares
−1.20K
Price / share
$46.41
Trade value
$55.69K
% of position
2.2%
9/9/2025
53.91K→52.71K
Common Stock
Direct
Shares
−2.16K
Price / share
$47.49
Trade value
$102.39K
% of position
4.1%
9/9/2025
52.71K→50.55K
Common Stock
Direct
Shares
−1.21K
Price / share
$48.18
Trade value
$58.30K
% of position
2.4%
9/9/2025
50.55K→49.34K
Total
Net shares
−6.67K
Net value
-$311.21K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/9/2025 | S · Sale | −2.10K | $45.16 | $94.84K | 3.7% | 56.01K | 53.91K |
| Common Stock Direct | 9/9/2025 | S · Sale | −1.20K | $46.41 | $55.69K | 2.2% | 53.91K | 52.71K |
| Common Stock Direct | 9/9/2025 | S · Sale | −2.16K | $47.49 | $102.39K | 4.1% | 52.71K | 50.55K |
| Common Stock Direct | 9/9/2025 | S · Sale | −1.21K | $48.18 | $58.30K | 2.4% | 50.55K | 49.34K |
| Total | −6.67K | -$311.21K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned28.00
Total
28.00 indirect28.00
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 28.00 | Indirect |
| Total | 28.00 | 28.00 indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported